Navigation Links
Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting

SAN DIEGO, June 20, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013.

ADA: McCormick Place Convention Center (West Building), Chicago, ILAbstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin

Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian

Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka

All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters.

Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
2. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
3. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
4. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
5. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
6. Orexigen Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
10. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
11. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
(Date:10/12/2015)... Center for Innovation announced today that Elizabeth ... th recipient of the CME Group Melamed-Arditti Innovation ... Theranos , to change health care from reactive to proactive, ... care. CME Group will present the award at the eighth ... Naples, Florida , on Tuesday, November 17. ...
(Date:10/12/2015)... PUNE, India , October 12, 2015 ... new market research report "Spirometer Market by Product (Hand-held, Table-top, ... (Hospital, Clinic, Homecare), Application, & Geography - Global Forecast to ... reach USD 858.6 Million by 2020, at a CAGR of ... data Tables and 128 F igures spread th ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
Breaking Medicine Technology:
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... Scientists ... versus tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just ... , The doctors from PhenoPath Laboratories in Seattle and the University of British ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... new School of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from ... education that has spanned four decades. , Dr. McLeod’s long and successful nursing ...
(Date:10/13/2015)... ... 13, 2015 , ... Breathing is one of the human ... According to T’ai Chi (also spelled “Taiji”) and Qigong Grand-masters Steven Aung, MD, ... with the 7,000 year old tradition they teach, can improve health, increase energy ...
(Date:10/13/2015)... ... 2015 , ... In an ongoing effort to provide the ... Texas, child development and pediatric therapy center, is working with TRICARE to emphasize ... options for receiving this kind of care for affected children. Because of concerns ...
(Date:10/13/2015)... Alpharetta, Georgia (PRWEB) , ... October 13, 2015 ... ... their leadership team: Debbie Vereb has been named the organization’s Executive Vice ... Tony Gerena, have been hired to key leadership roles in the company. , ...
Breaking Medicine News(10 mins):